Comprehensive Solutions For Clinical Development Of Generic Drugs

Syngene offers comprehensive solutions for clinical development of generic drugs. Our scientists have the skills and the capability to deliver great science on time and within budget while ensuring the highest levels of data integrity, IP security, and quality.

So far, we have completed ~700 Bioavailability/Bioequivalence (BA/BE) studies for global clients successfully.

Syngene's bioanalytical laboratory for small molecules has been inspected and approved by the US FDA, Brazil's National Health Surveillance Agency (ANVISA), Medicines and Healthcare products Regulatory Agency (MHRA), and the European Medicines Agency (EMA).